- Home
- RMAX vs ADVB Comparison
RMAX vs ADVB Comparison
Compare RMAX & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | ADVB |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | 31 |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3M | 109.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMAX | ADVB |
|---|---|---|
| Price | $6.16 | $4.02 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 217.6K | 97.2K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | $10.08 | ★ $1.26 |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.66 | $0.19 |
| 52 Week High | $10.32 | $5.82 |
Technical Indicators
Market Signals| Indicator | RMAX | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 57.46 |
| Support Level | $5.66 | $0.36 |
| Resistance Level | $8.47 | $5.71 |
| Average True Range (ATR) | 0.27 | 0.30 |
| MACD | 0.08 | -0.23 |
| Stochastic Oscillator | 71.09 | 27.33 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About ADVB Advanced Biomed Inc.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.